$RPTX
Repare Therapeutics Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040588 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $2.200M $30.25M $18.20M
YoY Change -98.05% 4354.93% 164.62%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.900M $8.719M $7.939M
YoY Change -0.05% 9.84% 3.93%
% of Gross Profit
Research & Development $32.71M $33.79M $29.89M
YoY Change 4.7% 7.35% 6.86%
% of Gross Profit
Depreciation & Amortization $500.0K $506.0K $455.0K
YoY Change 3.31% -3.25% 23.64%
% of Gross Profit
Operating Expenses $40.58M $42.51M $37.83M
YoY Change 3.66% 7.85% 6.23%
Operating Profit -$38.42M -$12.26M
YoY Change -152.34% -68.35%
Interest Expense $3.300M $3.448M $2.989M
YoY Change 53.27% 403.36% 5648.08%
% of Operating Profit
Other Income/Expense, Net $3.240M $3.422M $13.00K
YoY Change 53.12% 407.72% -165.0%
Pretax Income -$35.18M -$8.836M -$16.63M
YoY Change -146.58% -76.78% -42.06%
Income Tax -$16.30M $3.110M $15.03M
% Of Pretax Income
Net Earnings -$18.88M -$11.95M -$31.66M
YoY Change -125.02% -68.64% 11.91%
Net Earnings / Revenue -858.14% -39.49% -173.96%
Basic Earnings Per Share -$0.45 -$0.28
Diluted Earnings Per Share -$0.45 -$0.28 -$0.75
COMMON SHARES
Basic Shares Outstanding 42.09M 42.09M 41.96M
Diluted Shares Outstanding 42.10M 42.09M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $250.1M $280.7M $343.9M
YoY Change 61.16% 1.76% 2.84%
Cash & Equivalents $107.4M $115.5M $159.5M
Short-Term Investments $142.7M $165.1M $184.4M
Other Short-Term Assets $5.600M $4.201M $5.715M
YoY Change -0.62% 29.58% -9.49%
Inventory
Prepaid Expenses $5.551M $4.201M $5.715M
Receivables
Other Receivables $3.731M $5.281M $4.323M
Total Short-Term Assets $275.1M $291.9M $354.0M
YoY Change -29.57% 0.75% 0.73%
LONG-TERM ASSETS
Property, Plant & Equipment $4.722M $4.821M $4.228M
YoY Change 0.83% -5.91% -24.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $397.0K $408.0K $497.0K
YoY Change -20.12% -17.91% -15.19%
Total Long-Term Assets $11.31M $9.663M $10.10M
YoY Change -39.04% -47.21% -41.64%
TOTAL ASSETS
Total Short-Term Assets $275.1M $291.9M $354.0M
Total Long-Term Assets $11.31M $9.663M $10.10M
Total Assets $286.4M $301.6M $364.1M
YoY Change -30.0% -2.1% -1.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.438M $4.893M $461.0K
YoY Change -41.81% -1.96% -79.97%
Accrued Expenses $23.00M $23.70M $23.55M
YoY Change 31.53% 7.71% 17.93%
Deferred Revenue $20.47M $24.41M $53.10M
YoY Change -41.15% 105.92% 345.45%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.97M $53.25M $78.62M
YoY Change -20.85% 35.02% 124.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.100M $2.921M $5.939M
YoY Change -90.12% -93.22% -86.86%
Total Long-Term Liabilities $4.100M $2.921M $5.939M
YoY Change -90.12% -93.22% -86.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.97M $53.25M $78.62M
Total Long-Term Liabilities $4.100M $2.921M $5.939M
Total Liabilities $53.04M $56.17M $84.56M
YoY Change -48.7% -31.93% 5.31%
SHAREHOLDERS EQUITY
Retained Earnings -$305.1M -$286.2M -$239.3M
YoY Change 46.92% 1.09% 13.81%
Common Stock $538.7M $532.0M $519.3M
YoY Change 4.81% 4.6% 4.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $233.4M $245.4M $279.5M
YoY Change
Total Liabilities & Shareholders Equity $286.4M $301.6M $364.1M
YoY Change -30.0% -2.1% -1.26%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$18.88M -$11.95M -$31.66M
YoY Change -125.02% -68.64% 11.91%
Depreciation, Depletion And Amortization $500.0K $506.0K $455.0K
YoY Change 3.31% -3.25% 23.64%
Cash From Operating Activities -$32.87M -$34.35M -$29.64M
YoY Change -137.29% 21.82% 42.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.065M -$1.720M
YoY Change -100.0% -167.88% 942.42%
Acquisitions
YoY Change
Other Investing Activities $24.50M $29.42M $32.34M
YoY Change -111.74% 11213.46% -13978.97%
Cash From Investing Activities $24.50M $28.35M $34.06M
YoY Change -111.73% -2265.78% -8657.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 290.0K 40.00K 165.0K
YoY Change 7.81% -80.49% -99.83%
NET CHANGE
Cash From Operating Activities -32.87M -34.35M -29.64M
Cash From Investing Activities 24.50M 28.35M 34.06M
Cash From Financing Activities 290.0K 40.00K 165.0K
Net Change In Cash -8.080M -5.956M 4.586M
YoY Change -93.29% -79.67% -93.75%
FREE CASH FLOW
Cash From Operating Activities -$32.87M -$34.35M -$29.64M
Capital Expenditures $0.00 $1.065M -$1.720M
Free Cash Flow -$32.87M -$35.41M -$27.92M
YoY Change -137.17% 33.0% 35.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001808158
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39335
dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
7171 Frederick-Banting
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 2
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 1Z9
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
412-7018
dei Security12b Title
Security12bTitle
Common shares, no par value
dei Trading Symbol
TradingSymbol
RPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42094446
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115544000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159521000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
165148000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
184420000
CY2023Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
1751000
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
5281000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4323000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4201000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5715000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
291925000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
353979000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4821000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4434000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
408000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2023Q2 us-gaap Assets
Assets
301588000
CY2022Q4 us-gaap Assets
Assets
364075000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4893000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21628000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21645000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2320000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24412000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
53102000
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1240000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
53253000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78619000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2226000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3257000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
695000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2682000
CY2023Q2 us-gaap Liabilities
Liabilities
56174000
CY2022Q4 us-gaap Liabilities
Liabilities
84558000
CY2023Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42093946
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42093946
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42036193
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42036193
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
482739000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
482032000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49299000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37226000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-424000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-428000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-286200000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239313000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
245414000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
301588000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
364075000
CY2023Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
30249000
CY2022Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
679000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
35927000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
1087000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33788000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31475000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65618000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57933000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8719000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7938000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17248000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16717000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
42507000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
39413000
us-gaap Operating Expenses
OperatingExpenses
82866000
us-gaap Operating Expenses
OperatingExpenses
74650000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12258000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38734000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46939000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73563000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-41000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
141000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-97000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
124000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
3489000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
544000
us-gaap Investment Income Net
InvestmentIncomeNet
6916000
us-gaap Investment Income Net
InvestmentIncomeNet
673000
CY2023Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
26000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
11000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
41000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
19000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3422000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
674000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6778000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
778000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8836000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38060000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40161000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72785000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3110000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6726000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11946000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-38093000
us-gaap Net Income Loss
NetIncomeLoss
-46887000
us-gaap Net Income Loss
NetIncomeLoss
-72850000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-189000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-189000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12135000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38093000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46883000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72850000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42089530
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42089530
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41899509
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41899509
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42065237
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42065237
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41880666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41880666
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4755000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4745000
CY2022Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-38093000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
225517000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6062000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
193000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-34941000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
251244000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6265000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-189000
CY2023Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-11946000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
245414000
us-gaap Profit Loss
ProfitLoss
-46887000
us-gaap Profit Loss
ProfitLoss
-72850000
us-gaap Share Based Compensation
ShareBasedCompensation
12327000
us-gaap Share Based Compensation
ShareBasedCompensation
9500000
us-gaap Depreciation
Depreciation
947000
us-gaap Depreciation
Depreciation
1039000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1086000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1091000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-60000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
136000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3928000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-34000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
2609000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1518000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3072000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
988000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
389000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4429000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2698000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-17000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3334000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
72000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
460000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-2991000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-1322000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1172000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1123000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-30677000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1087000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66132000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58199000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1540000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2056000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
169000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5150000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
145796000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21664000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-906000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
233000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
409000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
213000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
453000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
446000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43977000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58593000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115544000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
275834000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
222000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
149000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2023Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
300000
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
135300000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
157900000
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
200000
CY2022Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
CY2023Q2 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2023Q2 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2023000
CY2022Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1280000
CY2023Q2 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1250000
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1525000
CY2023Q2 rptx Other Receivables Net Current Other
OtherReceivablesNetCurrentOther
2008000
CY2022Q4 rptx Other Receivables Net Current Other
OtherReceivablesNetCurrentOther
1518000
CY2023Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
5281000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4323000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3845000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5616000
CY2023Q2 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16592000
CY2022Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15078000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
941000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
680000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
250000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
271000
CY2023Q2 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21628000
CY2022Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21645000
CY2023Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
30249000
CY2022Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
679000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
35927000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
1087000
rptx Number Of Operating Leases
NumberOfOperatingLeases
4
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
593000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
615000
us-gaap Operating Lease Cost
OperatingLeaseCost
1186000
us-gaap Operating Lease Cost
OperatingLeaseCost
1231000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
32000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
46000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
16000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
60000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
33000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2023Q2 us-gaap Lease Cost
LeaseCost
685000
CY2022Q2 us-gaap Lease Cost
LeaseCost
656000
us-gaap Lease Cost
LeaseCost
1332000
us-gaap Lease Cost
LeaseCost
1347000
us-gaap Operating Lease Payments
OperatingLeasePayments
1202000
us-gaap Operating Lease Payments
OperatingLeasePayments
802000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
149000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M28D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.04
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
240000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P10Y
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.83
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8032902
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2215540
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.8
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16050
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
201651
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.76
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10030741
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16050
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.67
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.08
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.51
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0375
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0292
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0368
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M21D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8078
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7885
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8148
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7855
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6265000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4745000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12327000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6265000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4745000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12327000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11946000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-38093000
us-gaap Net Income Loss
NetIncomeLoss
-46887000
us-gaap Net Income Loss
NetIncomeLoss
-72850000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42089530
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42089530
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41899509
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41899509
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42065237
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42065237
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41880666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41880666
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74

Files In Submission

Name View Source Status
0000950170-23-040588-index-headers.html Edgar Link pending
0000950170-23-040588-index.html Edgar Link pending
0000950170-23-040588.txt Edgar Link pending
0000950170-23-040588-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20230630.htm Edgar Link pending
rptx-20230630.xsd Edgar Link pending
rptx-ex10_1.htm Edgar Link pending
rptx-ex10_2.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rptx-20230630_def.xml Edgar Link unprocessable
rptx-20230630_lab.xml Edgar Link unprocessable
rptx-20230630_pre.xml Edgar Link unprocessable
rptx-20230630_htm.xml Edgar Link completed
rptx-20230630_cal.xml Edgar Link unprocessable